These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of effector B cells by ibrutinib in systemic sclerosis. Einhaus J; Pecher AC; Asteriti E; Schmid H; Secker KA; Duerr-Stoerzer S; Keppeler H; Klein R; Schneidawind C; Henes J; Schneidawind D Arthritis Res Ther; 2020 Mar; 22(1):66. PubMed ID: 32228672 [TBL] [Abstract][Full Text] [Related]
4. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Flinsenberg TWH; Tromedjo CC; Hu N; Liu Y; Guo Y; Thia KYT; Noori T; Song X; Aw Yeang HX; Tantalo DG; Handunnetti S; Seymour JF; Roberts AW; Ritchie D; Koldej R; Neeson PJ; Wang L; Trapani JA; Tam CS; Voskoboinik I Haematologica; 2020; 105(2):e76-e79. PubMed ID: 31171645 [No Abstract] [Full Text] [Related]
5. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia. Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091 [TBL] [Abstract][Full Text] [Related]
6. Development of BTK inhibitors for the treatment of B-cell malignancies. Kim HO Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210 [TBL] [Abstract][Full Text] [Related]
9. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871 [TBL] [Abstract][Full Text] [Related]
10. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Al-Toubah T; Schell MJ; Cives M; Zhou JM; Soares HP; Strosberg JR Neuroendocrinology; 2020; 110(5):377-383. PubMed ID: 31357193 [TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of Waldenström macroglobulinemia. Despina F; Meletios Athanasios D; Efstathios K Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949 [TBL] [Abstract][Full Text] [Related]
12. Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue. Göckeritz E; Vondey V; Guastafierro A; Pizevska M; Hassenrück F; Neumann L; Hallek M; Krause G Br J Haematol; 2017 Sep; 178(6):949-953. PubMed ID: 28573668 [TBL] [Abstract][Full Text] [Related]
13. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
14. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164 [TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Whang JA; Chang BY Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226 [TBL] [Abstract][Full Text] [Related]
16. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100 [TBL] [Abstract][Full Text] [Related]
17. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Roskoski R Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927 [TBL] [Abstract][Full Text] [Related]
18. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649 [TBL] [Abstract][Full Text] [Related]
19. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062 [TBL] [Abstract][Full Text] [Related]